A lysostaphin variant and its expression method in probiotics and its application
By introducing the E252C/N319C mutation into lysostaphin and combining it with short peptide modification, the thermostability of the enzyme was improved, and constitutive expression was achieved in probiotic EcN, thus solving the problem of enzyme thermostability and realizing effective sterilization application in milk.
Patent Information
- Application Number
- CN202310295225.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-03-23
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2043-03-23
AI Technical Summary
The poor thermostability of existing lysostaphin enzymes limits their application in the treatment of bacterial infections in animals and in the food additive industry, and heterologous expression has not been effectively achieved in probiotics.
By mutating lysostaphin based enzymes, especially the E252C/N319C mutation, and expressing it in probiotic EcN, combined with short peptide modification to improve the enzyme's thermostability, and by modifying the recombinant expression vector, constitutive secretion and expression were achieved.
A recombinant lysostaphin variant with good bactericidal activity and broad spectrum was obtained, which can effectively kill Staphylococcus aureus in buffer and milk, providing a low-cost food sterilization method.
Smart Images

Figure CN116179520B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of microbial technology and enzyme engineering, and particularly relates to a lysostaphin variant and a method for expressing the variant in probiotics and application thereof. Background Art
[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.
[0003] Staphylococcus aureus is one of the most notorious and widespread bacterial pathogens, which not only causes an incalculable number of simple skin infections worldwide each year. It is also the main pathogen of pneumonia and other respiratory infections, surgical sites, prosthetic joints, cardiovascular disease and nosocomial bacteremia, causing a large number of serious invasive infections. Mastitis is a common disease in dairy cows, with a high incidence, rapid epidemic rate and great difficulty in prevention and control. It not only causes serious economic losses to dairy farmers, but also causes serious food safety problems. Staphylococcus aureus is one of the most important pathogens causing mastitis in dairy cows.
[0004] Lysostaphin is a zinc-dependent glycine endopeptidase that can effectively cleave the cell wall of Staphylococcus aureus and was originally secreted by Staphylococcus aureus. It has now entered clinical research as a new antibacterial agent for the treatment of Staphylococcus aureus infections in wounds. The mature staphylococcal enzyme consists of two domains: the N-terminal peptidase domain involved in the catalytic activity of the enzyme and the C-terminal domain that binds to peptidoglycan. The activity of mature lysostaphin is 4.5 times that of prolysostaphin. The molecular weight of lysostaphin is about 27 kDa, the isoelectric point is about 9.5, and it does not contain sulfhydryl groups. However, the thermal stability of lysostaphin is poor, and its activity suddenly decreases when it is kept at 55°C for 30 minutes. This affects its wide application in the treatment of bacterial infections in animals and the food additive industry. Therefore, it is necessary to improve the thermal stability of lysostaphin through protein engineering.
[0005] Currently, lysostaphin products are commercially available. Although Staphylococcus aureus is primarily a human pathogen, it is also the main pathogen of bovine mastitis, which is the most common problem in the global dairy industry. Bovine mastitis is the main cause of reduced milk production and quality. Injecting lysostaphin into the udder of dairy cows helps to reduce the number of Staphylococcus aureus in milk. It is reported that the bactericidal activity of lysostaphin in milk is 10 to 100 times lower than that in laboratory culture media. In this context, it is very important to develop a new technology for sterilization and preservation of milk. Preferably, probiotics expressing lysostaphin have the effect of lysing Staphylococcus aureus in milk and have potential application prospects in animal husbandry.
[0006] So far, lysostaphin has been cloned and produced in a variety of expression systems by genetic engineering. Heterologously expressed lysostaphin has no essential difference from natural lysostaphin in terms of physicochemical properties and enzyme activity. The enzyme activity and yield of lysostaphin protein can be improved by heterologous expression and condition optimization. In 1987, recombinant lysostaphin was first expressed in Escherichia coli. Since 1990, a variety of prokaryotic expression systems have been reported, such as Escherichia coli, Bacillus (Bacillus subtilis, etc.), as well as in eukaryotic expression systems, mainly in Pichia pastoris. However, the expression of lysostaphin using the probiotic Escherichia coli Nissle1917 (EcN) has not been reported. Probiotics are living microorganisms that benefit the health of the host. More importantly, EcN is a promising candidate for probiotic properties and one of the most studied probiotics. Drugs can be produced and delivered as bacterial carriers. To our knowledge, EcN has only been used to produce omega-3 fatty acids, hepatic acid and 5-aminolevulinic acid. And the use of probiotics expressing Staphylococcus aureus to control bacterial infections has not been reported. Compared with BL21 (DE3) and MG1655, EcN has a lower expression level of ribosomal proteins. The EcN strain lacks the T7 RNA polymerase gene. However, by introducing the T7 RNA polymerase-dependent transcription system and improving the expression of ribosomal proteins, EcN can be developed into a new biotechnology expression platform. Summary of the invention
[0007] In view of the problems existing in the prior art, the present invention provides a lysostaphin variant and a method for expressing the same in probiotics and its application. The present invention secretes and expresses recombinant lysostaphin in probiotics EcN, and the obtained recombinant lysostaphin has good bactericidal activity and a wide antibacterial spectrum. In addition, compared with the wild protein, the combined mutant protein E252C / N319C-GGG has the highest thermal stability. It is worth noting that lysostaphin or EcN expressing lysostaphin has good bactericidal activity in buffer and milk, and the probiotic EcN expressing hemolytic Staphylococcus or its mutant has potential application value in food disinfection. Based on the above research results, the present invention is completed.
[0008] Specifically, the present invention relates to the following technical solutions:
[0009] The first aspect of the present invention provides a lysostaphin variant, wherein the lysostaphin variant is mutated on the basis of lysostaphin, and the lysostaphin variant is selected from the mutants shown below:
[0010] Mutant: E252C / N319C;
[0011] The lysostaphin variant is further modified with a short peptide, thereby further improving the heat stability of the lysostaphin variant.
[0012] The amino acid numbering adopts the residue numbering of PDB: 4LXC (https: / / www.rcsb.org / structure / 4LXC). Specifically, in the PDB database, the first amino acid residue alanine (Ala, A) in the amino acid sequence shown in SEQ ID NO.1 (AATHEHSAQWLNNYKKGYGYGPYPLGINGGMHYGVDFFMNIGTPVKAIS SGKIVEAGWSNYGGGNQIGLIENDGVHRQWYMHLSKYNVKVGDYVKAGQIIGWSGSTGYSTAPHLHFQRMVNSFSNSTAQDPMPFLKSAGYGKAGGTVTPTPNTGWKTNKYGTLYKSESASFTPNTDIITRTTGPFRSMPQSGVLKAGQTIHYDEVMKQDGHVWVGYTGNSGQRIYLPVRTWNKSTNTLGVLWGTIK) is used as the 248th amino acid residue position, and the numbering is sequentially postponed.
[0013] The short peptide may be a flexible short peptide, specifically (G4S) n and / or (GGG) n , wherein n is a natural number from 1 to 5, more specifically, n is 1; the short peptide can be modified at the end (amino end and / or carboxyl end) of the lysostaphin variant. In a specific embodiment of the present invention, the short peptide is modified at the carboxyl end of the lysostaphin variant.
[0014] The second aspect of the present invention provides a polynucleotide encoding the lysostaphin variant described in the first aspect.
[0015] The third aspect of the present invention provides a recombinant expression vector, which contains at least the polynucleotide described in the second aspect.
[0016] The fourth aspect of the present invention provides a host cell, wherein the host cell contains the vector described in the third aspect or the chromosome in which the polynucleotide described in the second aspect is integrated.
[0017] The fifth aspect of the present invention provides a microbial agent comprising the host cell or its fermentation product or its metabolite as described in the fourth aspect.
[0018] In particular, the host cell may be a bacterium or a fungus, and is particularly preferably a recombinant Escherichia coli EcN.
[0019] The metabolites described in the present invention include intracellular metabolites and / or extracellular metabolites.
[0020] The seventh aspect of the present invention provides a method for sterilizing food, which comprises adding the host cell described in the fourth aspect or the microbial agent described in the fifth aspect to the food.
[0021] Wherein, the sterilization may be to kill Staphylococcus, and the Staphylococcus further includes Staphylococcus aureus.
[0022] The food can be a food that is (susceptible to) Staphylococcus infection, especially a liquid food, such as milk and dairy products (milk), etc. By adding the above-mentioned host cells (or microbial agents) into the above-mentioned liquid food, co-cultivation with Staphylococcus aureus in the food is achieved, thereby achieving the purpose of killing and controlling the growth of pathogens.
[0023] Beneficial technical effects of one or more of the above technical solutions:
[0024] The above technical solution provides a method for realizing constitutive secretion and expression of lysostaphin in probiotic EcN, and the obtained recombinant lysostaphin has good bactericidal activity and relatively broad spectrum. The lysostaphin is further directed to be modified to obtain a mutant protein with higher thermal stability than the original protein.
[0025] Based on the above characteristics, the above technical scheme establishes a low-cost and simple method, that is, a method of controlling the growth of pathogenic bacteria by co-culturing EcN-Lys with pathogenic Staphylococcus aureus in food (milk). It lays a foundation for the application of lysostaphin in the food sterilization industry, and therefore has good practical application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.
[0027] Figure 1 The expression and analysis of lysostaphin in the embodiment of the present invention. A is the three-dimensional structure simulation and active site labeling of lysostaphin, B is the SDS-PAGE map of EcN expressing lysostaphin, lane 1 is the fermentation broth supernatant, lane 2 is the supernatant of the broken liquid, and lane 3 is the purified protein sample.
[0028] Figure 2is the enzymatic activity of the lysostaphin in the embodiment of the present invention, wherein A indicates that the EcN strain can secrete and express active lysostaphin, B is the plate inhibition graph of the EcN / 28a-Lys strain, C is the plate inhibition graph of the EcN / 28a strain, and D is the bactericidal activity graph of EcN / 28a-Lys.
[0029] Figure 3 1 is the effect of lysostaphin on Staphylococcus aureus in the embodiment of the present invention, wherein A and B are the morphological images of untreated Staphylococcus aureus cells at different magnifications, and C and D are the morphological images of Staphylococcus aureus cells at different magnifications after being treated with lysostaphin.
[0030] Figure 4 It is the detection of the basic properties of lysostaphin in the embodiment of the present invention, wherein A is the optimal temperature for screening lysostaphin, B is the optimal pH for lysostaphin, C is the effect of high temperature on the activity of lysostaphin, and D is the effect of divalent metal cations on the activity of lysostaphin.
[0031] Figure 5 The thermal stability and lytic activity of the lysostaphin and its combined mutants in the examples of the present invention.
[0032] Figure 6 is the colony reduction unit of Staphylococcus aureus treated with lysostaphin in the embodiment of the present invention, wherein A is a milk system and B is a buffer reaction system.
[0033] Figure 7 The partial map sequence of the original plasmid after transformation in the invention example is shown, A is the original plasmid pET28a-Lys, and B is the transformed plasmid pET28a-Lys (To).
[0034] Figure 8 The bactericidal activity of constitutively expressing lysostaphin after plasmid modification in the present invention. A is the bactericidal activity of lysostaphin in the supernatant of fermentation broth induced by EcN-Lys(T) and EcN-Lys(To), and B is the bactericidal activity of lysostaphin in the supernatant of crushed broth induced by EcN-Lys(T) and EcN-Lys(To).
[0035] Fig. 9 In the embodiment of the present invention, the 7 -10 8 ) At the initial concentration of Staphylococcus aureus, EcN-Lys reduced the number of Staphylococcus aureus colonies in milk at different time periods. DETAILED DESCRIPTION
[0036] It should be noted that the following detailed descriptions are illustrative and are intended to provide further explanation of the present application. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present application belongs.
[0037] It should be noted that the terms used here are only for describing specific embodiments, and are not intended to limit the exemplary embodiments according to the present application. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should also be understood that when the terms "comprising" and / or "including" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof. If the experimental methods of specific conditions are not indicated in the following specific embodiments, the conventional methods and conditions of molecular biology in the art are usually followed, and such techniques and conditions are fully explained in the literature. See, for example, Sambrook et al., the techniques and conditions described in "Molecular Cloning: Laboratory Manual", or according to the conditions recommended by the manufacturer.
[0038] In a typical embodiment of the present invention, a lysostaphin variant is provided, wherein the lysostaphin variant is mutated on the basis of lysostaphin, and the lysostaphin variant is selected from the mutants in the following group:
[0039] Provided is a lysostaphin variant, wherein the lysostaphin variant is mutated on the basis of lysostaphin, and the lysostaphin variant is selected from the mutants shown below:
[0040] Mutant: E252C / N319C;
[0041] The lysostaphin variant is further modified with a short peptide, thereby further improving the heat stability of the lysostaphin variant.
[0042] The amino acid numbering adopts the residue numbering of PDB: 4LXC (https: / / www.rcsb.org / structure / 4LXC). Specifically, in the PDB database, the first amino acid residue alanine (Ala, A) in the amino acid sequence shown in SEQ ID NO.1 (AATHEHSAQWLNNYKKGYGYGPYPLGINGGMHYGVDFFMNIGTPVKAIS SGKIVEAGWSNYGGGNQIGLIENDGVHRQWYMHLSKYNVKVGDYVKAGQIIGWSGSTGYSTAPHLHFQRMVNSFSNSTAQDPMPFLKSAGYGKAGGTVTPTPNTGWKTNKYGTLYKSESASFTPNTDIITRTTGPFRSMPQSGVLKAGQTIHYDEVMKQDGHVWVGYTGNSGQRIYLPVRTWNKSTNTLGVLWGTIK) is used as the 248th amino acid residue position, and the numbering is sequentially postponed.
[0043] The short peptide may be a flexible short peptide, specifically (G4S) n and (GGG) n , wherein n is a natural number from 1 to 5, more specifically, n is 1; the short peptide can be modified at the end (amino end and / or carboxyl end) of the lysostaphin variant. In a specific embodiment of the present invention, the short peptide is modified at the carboxyl end of the lysostaphin variant.
[0044] In another specific embodiment of the present invention, a polynucleotide is provided, wherein the polynucleotide encodes the above-mentioned lysostaphin variant.
[0045] In another specific embodiment of the present invention, a recombinant expression vector is provided, wherein the recombinant expression vector contains the above-mentioned polynucleotide of the present invention.
[0046] In another specific embodiment of the present invention, the recombinant expression vector is obtained by effectively connecting the above-mentioned polynucleotide to an expression vector, and the expression vector is any one or more of a viral vector, a plasmid, a phage, a phagemid, a cosmid or an artificial chromosome; the viral vector may include an adenovirus vector, a retrovirus vector or an adeno-associated virus vector, and the artificial chromosome includes a bacterial artificial chromosome, a phage P1-derived vector, a yeast artificial chromosome or a mammalian artificial chromosome; preferably, the expression vector is a plasmid, and in a specific embodiment of the present invention, the plasmid is pET28a.
[0047] In another specific embodiment of the present invention, since the PET28a expression vector has a T7 promoter and a Tac regulator, a relatively high initial concentration of isopropyl-β-D-thiogalactoside (IPTG) is required to initiate effective expression. In order to enable the subsequent recombinant probiotics (EcN) to express the above-mentioned lysostaphin variant under IPTG-free induction conditions, thereby avoiding the potential toxicity of IPTG in practical applications, especially in the food field, it is necessary to further modify the recombinant expression vector.
[0048] Specifically, since the EcN strain lacks the T7 RNA polymerase gene, the first step of the transformation is to replace the inherent T7 promoter on the pET28a(+) vector with the Tac promoter. This process can be achieved by recombination and other means. In addition, under normal circumstances, the E. coli I gene encodes a repressor protein (LacI) that binds to the O sequence, thereby keeping the operon in a closed state. Therefore, the site of the Lac O operator on the pET28a(+) vector is mutated so that it cannot bind to the Lac repressor (LacI), thereby obtaining a non-inducible promoter.
[0049] It should be noted that the applicant unexpectedly found in the previous study that if LacO is directly removed, lysostaphin will not be secreted, and the supernatant of the fermentation broth and the supernatant of the broken broth have no bactericidal activity. It is speculated that after LacO is removed, the promoter and the start codon are too close, resulting in the inability of protein expression. This shows that LacO has the necessity of existence. Therefore, it was decided to adopt the above mutation method. In a specific embodiment of the present invention, the four sites of LacO (-4, -2, +2, +4 are mutated to TATA) are mutated.
[0050] In another specific embodiment of the present invention, a host cell is provided, wherein the host cell contains the above-mentioned recombinant expression vector or the above-mentioned polynucleotide is integrated into the chromosome.
[0051] The host cell may be a prokaryotic cell or a eukaryotic cell.
[0052] In another embodiment of the present invention, the host cell is a bacterial cell or a fungal cell;
[0053] wherein the bacterial cell is of the genus Escherichia, Agrobacterium, Bacillus, Streptomyces or Pseudomonas;
[0054] In another specific embodiment of the present invention, the bacterial cell is Escherichia coli EcN, which is a probiotic, safe and healthy, and can be used in fields such as food sterilization.
[0055] The fungal cells include yeast (eg, Pichia pastoris).
[0056] In another specific embodiment of the present invention, a microbial agent is provided, which comprises the above-mentioned host cell or its fermentation product or its metabolite.
[0057] In particular, the host cell may be a bacterium or a fungus, and is particularly preferably a recombinant Escherichia coli EcN.
[0058] The metabolites described in the present invention include intracellular metabolites and / or extracellular metabolites, and in particular, include the above-mentioned lysostaphin variant.
[0059] The term "fermentation product" is used to refer to a fermentation product. The corresponding fermentation product may be a liquid obtained from the process of fermenting and culturing recombinant E. coli EcN, and therefore, may also be referred to as a fermentation broth; the liquid may contain bacteria (bacteria), but does not necessarily need to contain bacteria. The liquid preferably contains metabolites produced by the recombinant E. coli EcN of the present invention (particularly, including the above-mentioned lysostaphin variant).
[0060] Also, in an embodiment of the present invention, the fermentation liquid or culture liquid containing the bacteria is centrifuged, filtered, sedimented or other means known in the art to separate the bacterial cells grown in the fermentation liquid or culture liquid from the liquid, and the liquid remaining after removing the bacterial cells is the "supernatant", and in the present invention, the supernatant contains the extracellular metabolites of the recombinant Escherichia coli EcN. In an embodiment of the present invention, the bacterial agent may also include the supernatant.
[0061] And, in an embodiment of the present invention, the fermentation liquid or culture liquid containing the bacteria is centrifuged, filtered, sedimented or other means known in the art to separate the bacterial cells grown in the fermentation liquid or culture liquid from the liquid to obtain the bacteria, and the bacteria can be crushed to obtain the bacterial crushed material, and the crushing method can be ultrasound (such as ice bath ultrasonic cell crushing) or other means known in the art, or, further, the bacterial crushed material is centrifuged to collect the supernatant, and the supernatant is recorded as a cell-free extract, and in the present invention, the bacterial crushed material or cell-free extract contains the intracellular metabolites of recombinant Escherichia coli EcN. In an embodiment of the present invention, the bacterial agent may also include the bacterial crushed material or cell-free extract.
[0062] In another specific embodiment of the present invention, there is provided application of the above-mentioned lysostaphin variant, polynucleotide, recombinant expression vector, host cell or microbial agent in the field of food sterilization.
[0063] Among them, in actual applications, the application environment can be a normal temperature or a high temperature environment, and the high temperature environment is not less than 30°C (for example, 30°C-40°C, 40°C-50°C or 50°C-60°C); further, it is not less than 60°C (for example, 60°C-70°C or higher, or 60°C, 61°C, 62°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C).
[0064] In another specific embodiment of the present invention, a method for sterilizing food is provided, the method comprising adding the above-mentioned host cells or microbial agents into the food.
[0065] Wherein, the sterilization may be to kill Staphylococcus, and the Staphylococcus further includes Staphylococcus aureus.
[0066] The food can be a food that is (susceptible to) Staphylococcus infection, especially a liquid food, such as milk and dairy products (milk), etc. By adding the above-mentioned host cells (or microbial agents) into the above-mentioned liquid food, co-cultivation with Staphylococcus aureus in the food is achieved, thereby achieving the purpose of killing and controlling the growth of pathogens.
[0067] In particular, the host cell used in the present invention is the probiotic EcN, which is safe and harmless to the human body and is therefore more suitable for the field of food sterilization.
[0068] The present invention is further explained by the following examples, but they are not intended to limit the present invention. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention.
[0069] Example
[0070] 1. Materials and Methods
[0071] 1.1 Bacterial strains and growth conditions
[0072] The amino acid sequence of Staphylococcus aureus was queried and downloaded from NCBI, codon optimized, biotechnologically synthesized genes, and ligated into the pET28a(+) expression vector. The strains and pathogens used to test the antimicrobial spectrum in this work are listed in Table 1. Escherichia coli DH5α competent cells were purchased from Wei Di Biotechnology Co., Ltd. (Shanghai, China), and EcN competent cells were prepared by the calcium chloride method. Escherichia coli cells were grown in Luria-Bertani (LB) medium.
[0073] Table 1 Strains, plasmids and primers used in this study
[0074]
[0075]
[0076] 1.2. Cloning, expression and purification of lysostaphin and mutant strains
[0077] The gene encoding lysostaphin (GCAGCAACCCATGAACATAGTGCCCAGTGGCTGAATAATTAT) and Lys-R (TTTAATGGTGCCACACAGCACGCCCAGGG) was amplified using a pair of primers, and cloned into the vector pET28a(+) by seamless cloning to obtain the expression plasmid pET28a(+)-Lys. EcN transformants were further obtained and incubated at 37°C until OD 600nmThe pH value was 0.6 to 0.8. IPTG (0.5 mM) was added to the culture medium to induce the expression of lysostaphin at 37°C for 36 h. The cells were collected by centrifugation (6800 × g, 4°C, 10 min) and suspended in 10 mL of lysis buffer containing 50 mM sodium phosphate (pH 7.0) and 300 mM NaCl. The cells were then sonicated using an ultrasonic disruptor JY92 II (Ningbo Science Biotechnology Co., Ltd., China) for 99 cycles of 4 s pulses and 8 s pauses.
[0078] We designed the corresponding primers for the mutant protein expressing the same lysostaphin. Then, we used the pET28a(+)-Lys plasmid as a template for directed mutagenesis. 1 μL of DpnI enzyme was added to the PCR product, and the template was digested at 37°C for 2 h. The seamless assembly mixture was incubated at 50°C for 30 min in a PCR instrument and then transferred to E. coli DH5α to further obtain E. coli EcN expressing the mutant protein. Protein expression was induced under the same conditions as the EcN strain (containing the plasmid pET28a(+)-Lys).
[0079] 1.3. Staphylococcus aureus activity assay
[0080] 1.3.1. Plate inhibition test
[0081] Take Staphylococcus aureus frozen in -80℃ refrigerator, inoculate 2% in 5mL liquid LB medium and culture for 16h. The next day, transfer 2% inoculation to 100mL liquid LB medium for 3-4h, and wait for its OD 600nm =0.8, centrifuge at 7000 rpm for 10 minutes at 4°C, discard the supernatant, and suspend the precipitate with physiological saline to OD 600nm =2.5. After the bacterial suspension was inactivated in an 80°C water bath for 10 minutes, 12.5 mL of the inactivated bacterial suspension was added to the melted 50 mL of solid LB medium and quickly poured onto the plate. Thus, we obtained a double-layer plate carrying Staphylococcus aureus. After the culture medium in the plate was cooled and solidified, the first method was to punch the culture medium, and 10 μL of lysostaphin and the control were respectively applied to the holes of the above plate, and then placed in a 37°C constant temperature incubator. After 12 hours, the plate inhibition zone was observed. On the other hand, the EcN expression strain expressing lysostaphin and its mutants was diluted to an appropriate multiple and coated on the above double-layer plate, placed in a 37°C incubator for 24 hours, and the transparent zone around the colony was observed.
[0082] 1.3.2. Liquid enzyme activity assay
[0083] Liquid enzyme activity detection was performed in an ELISA instrument. The turbidity method steps were as follows: Take frozen Staphylococcus aureus strains, inoculate 2% of the strains in 5 mL of LB medium and culture overnight for about 16 hours to obtain first-level seeds. Take first-level seeds, inoculate 2% of the strains in 50 mL of LB medium and culture for 5 to 6 hours until the OD 600 nm =2.0. Pour the cultured bacterial solution into a 50mL centrifuge tube, centrifuge at 7000rpm for 10min, discard the supernatant, wash the bacteria with 25mL PBS buffer, blow and wash repeatedly, then centrifuge at 7000rpm for 10min; repeat the above steps twice. Discard the supernatant, get the final bacteria, and suspend them with PBS to OD 600nm =0.8, preheat the water bath at 37℃ for 10min. Add 10μL of sample to the 96-well plate, add 190μL of treated Staphylococcus aureus suspension with a spray gun, and place in the microplate reader for detection. The microplate reader program settings are as follows: temperature set to 37℃, running time 30min, time interval 1min, wavelength 600nm.
[0084] 1.4. Scanning electron microscopy observation
[0085] Staphylococcus aureus was reacted with lysostaphin at 37°C for 5 minutes, centrifuged under 1×PBS, and the precipitate was fixed with 2.5% glutaraldehyde for 3 hours, fixed with 2.5% glutaraldehyde and dehydrated with ethanol aqueous solution of different concentrations, and dried with a critical point dryer. Then, after gold spraying, the sample was observed with a field emission scanning electron microscope (Quanta 250FEG), and Staphylococcus aureus that did not react with the enzyme was used as a control.
[0086] 1.5. Detection of the properties of lysostaphococcosis
[0087] 1.5.1. Optimal pH and temperature for bactericidal activity of lysostaphin
[0088] To determine the optimal reaction temperature for lysostaphin, logarithmically growing Staphylococcus aureus cells were resuspended to approximately OD 600nm The optimal temperature of lysostaphin was evaluated in the temperature range of 20-50°C according to the standard assay. The optimal pH of lysostaphin was determined by measuring the enzyme activity as described above in various buffers with pH values ranging from 3.0 to 12.0 at the optimal temperature (37°C). The ΔOD of the strain treated with lysostaphin for 5 min was plotted against the reaction temperature and pH as the horizontal axis. 600 nm The vertical axis is the histogram of the optimal temperature and pH.
[0089] 1.5.2. Thermal stability determination of Staphylococcus aureus and its variants
[0090] In order to test the heat resistance of lysostaphin, the enzyme solution was diluted to an appropriate concentration and kept at different temperatures (20°C, 25°C, 30°C, 35°C, 37°C, 40°C, 45°C, 50°C, 55°C, 60°C) for half an hour, and immediately taken out of the ice bath for 30 minutes. The enzyme reaction was carried out under the optimal conditions, the residual enzyme activity was determined, and finally, the thermal stability of lysostaphin and its mutants was determined.
[0091] 1.5.3. Effects of metal ions on the activity of lysostaphococcosis
[0092] In order to detect the sensitivity of lysostaphin, ZnCl2, MnCl2·4H2O, MgCl2·6H2O, CuCl2·2H2O and CaCl2 were added to the enzyme activity detection system to make the final concentrations of 0.5mM and 1.0mM, respectively, and the enzyme activity was detected in an enzyme labeling instrument.
[0093] 1.6. Antimicrobial spectrum of lysostaphin
[0094] A total of 9 Gram-positive Staphylococcus aureus (TA22, DZ02, DZ04, LY05, LY53, Sa.2-3, Sa.2HUN, WF107 and ATCC6538) and 5 Gram-negative bacteria (E.coil DH5α, BL21(DE3), JM109, MG1655 and Min O157) were used to detect the inhibition spectrum. The culture medium was incubated at 37°C and 220 r / min until OD 600nm = 1.2, centrifuge the bacteria, resuspend the pellet, wash twice with 20 mM Tris HCl (pH 8.0), and adjust the OD of the bacterial suspension with Tris-HCl buffer. 600nm To 1.0, wherein the outer membrane of the above Gram-negative strain was destroyed by EDTA. Staphylococcus aureus with a final concentration of 10.0 μg / mL was mixed with the bacterial suspension and reacted for 30 minutes, and sodium phosphate buffer was used instead of lysostaphin as a control. The lytic activity was calculated by using the formula: Relative lytic activity (%) = 100 × ΔOD 600nm Initial OD of mixture with Lysostaphin / control 600nm .
[0095] 1.7. Design of Staphylococcus aureus mutants
[0096] 1.7.1. Modification of metal ion binding sites: introduction of disulfide bonds
[0097] Molecular dynamics simulation of lysostaphin (Pdbid: 4LXC) in Zn 2+ The concentration was 0.15 mol / L and the temperature was 310 K for 20 ns. 2+The percentage of the binding time of ions at different amino acid residue sites in the entire simulation time was used to identify Zn 2+ The key amino acid residues for ion binding. 2+ Effects of ions on the activity or thermal stability of lysostaphin 2+ Disulfide bonds were designed at the key amino acid residue sites for the binding of ions to lysostaphin.
[0098] 1.7.2. Modification of lysostaphin: introduction of short peptides
[0099] By connecting the coding genes of short peptides G4S and GGG to the expression vector pET28a(+)-Lys, expression strains of Staphylococcus aureus mutants containing different short peptides (the short peptides were all modified at the carboxyl terminus of the Staphylococcus aureus mutants) were constructed.
[0100] 1.7.3. Design of combined mutants
[0101] In order to further improve the thermal stability of the variants, a short peptide G4S or GGG was added to the carboxyl terminus of the disulfide bond optimal mutant protein N319C / E252C, combining these two strategic mutations and obtaining a mutant with combined mutations.
[0102] 1.8. Sterilization of Staphylococcus aureus under different conditions
[0103] 1.8.1. Colony forming units of lysostaphin in buffer and milk
[0104] Colony forming units (CFU): S. aureus was treated as described above and the cell pellet was resuspended in buffer (20 mM Tris–HCl (pH 8.0)) or milk (2%) to approximately OD 600nm ≈1.0, and the final concentration of 10.0 μg / mL of Staphylococcus aureus was mixed with Staphylococcus aureus. Then, the mixture was reacted in a shaker at 37°C and samples were regularly spread on the plate. Finally, the total number of bacterial colonies remaining was calculated after culturing at 37°C for 12 hours.
[0105] 1.8.2. Construction of EcN strain constitutively expressing lysostaphin
[0106] In order to obtain a constitutively expressed EcN strain and avoid the potential toxicity of IPTG in practical applications. Therefore, the pET28a(+)-Lys plasmid was modified. First, compared with BL21(DE3) and MG1655, EcN has a lower ribosomal protein expression level. Because the EcN strain lacks the T7 RNA polymerase gene, the first step of the transformation is to replace the inherent T7 promoter on the pET28a(+) vector with a Tac series promoter by recombination. Under normal circumstances, the Escherichia coli I gene encodes a repressor protein (LacI) that binds to the O sequence, keeping the operator in a closed state. The site of the Lac O operator is mutated so that it cannot bind to the Lac repressor factor (LacI), thereby obtaining a non-inducible promoter.
[0107] First, because the EcN strain lacks the T7 RNA polymerase gene, the promoter was replaced with Tac. The plasmid pET28a(+)-Lys was amplified using a pair of primers Tac-FP (TGACAATTAATCATCGGCTCGTATAATGGGAATTGTGAGCGGATAACAAT TC, SEQ ID NO.3) and Tac-RP (GAGCCGATGATTAATTGTCAATCTCGATCCTCTACGCCG, SEQ ID NO.4) to obtain the plasmid pET28a(+)-Lys(T), which was replicated by DH5α and transformed into EcN to obtain the transformant EcN-Lys(T), which was induced to express protein under the same conditions as the above-mentioned EcN (containing plasmid pET28a(+)-Lys) strain. The protein expression was detected by SDS-PAGE, and the bactericidal activity was detected by turbidity. On the other hand, to avoid the potential toxic effects of IPTG in practical applications, preliminary experiments have found that after LacO is removed, lysostaphin is not secreted, and the supernatant of the fermentation broth and the supernatant of the broken broth have no bactericidal activity. It is speculated that after LacO is removed, the distance between the promoter and the start codon is too close, resulting in the inability of protein expression (data not shown), which shows that LacO is inevitable. Then the four sites of LacO (-4, -2, +2, +4 positions are mutated to TATA). The pET28a(+)-Lys(T) plasmid was amplified by PCR using primers TATA-FP (TAACGGTTAACAATTCCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAG GAG, SEQ ID NO.5) and TATA-RP (CAAAATTATTTCTAGAGGGGAATTGTTAACCGTTAACAATTCCCATTATA CGAGCCGATG, SEQ ID NO.6) to obtain plasmid pET28a(+)-Lys(To) and further obtain transformant EcN-Lys(To). The strain EcN-Lys(To) was inoculated with 2% seed solution and cultured at 37°C for 36 hours. The fermentation supernatant and crude enzyme solution were collected and the enzyme activity was detected. 1.8.3 Colony forming units of Staphylococcus aureus co-cultured with EcN
[0108] In order to reduce the cost and loss of enzyme extraction and purification, an attempt was made to use probiotic EcN whole cells expressing lysostaphin to eliminate pathogenic Staphylococcus aureus in milk. The EcN strain expressing lysostaphin and Staphylococcus aureus were activated separately. In a 12-well plate, 3 mL of pasteurized skim milk was added, and the strain with an inoculum of 3% EcN was infected with 3% of Staphylococcus aureus inoculum at the same time, and placed in a 37°C constant temperature incubator for co-culture. About 100 μL of culture solution was taken out at a fixed point and diluted to an appropriate multiple and then spread, and then the changes in Staphylococcus aureus colonies were calculated.
[0109] Statistical analysis
[0110] The data in this study are the means of triplicates, and the standard deviations are presented as error bars. Statistical tests were performed using SPSS 22.0 for Windows (SPSS Inc., USA).
[0111] 2. Results and Discussion
[0112] 2.1. Bioinformatics analysis, cloning and expression of lysostaphin
[0113] The primary and tertiary structures of lysostaphin were analyzed by bioinformatics, and its possible catalytic residues were identified. According to the genome sequence of lysostaphin (GenBank accession KF724949), it consists of a single-chain molecule of 246 amino acids, bound to a zinc ion. In the lysostaphin protein structure database (PDB) Pdbid: 4LXC, the three-dimensional model shows that the two domains of lysostaphin are mainly composed of folds and irregular coils ( Figure 1 A). It contains two independent domains (the catalytic domain at the N-terminus and the cell wall binding domain at the C-terminus), connected by a flexible linker of 17 aa. The bacterial cell wall binding domain has an active groove that specifically binds to the peptidoglycan in the cell wall of Staphylococcus aureus in a cross-linked state.
[0114] First, the gene fragment encoding Staphylococcus lysogenus was connected to the expression vector pET28a(+) to successfully construct pET28a-Lys. EcN containing the recombinant plasmid was induced to secrete with IPTG (0.5 mM) at 37 °C for 36 h, and the recombinant protein was detected by SDS-PAGE analysis ( Figure 1B). The band size of the detected recombinant protein is similar to the approximately 27.1 kDa predicted by ExPASy. Soluble protein is present in both the fermentation broth supernatant and the supernatant of the disrupted broth. Lysostaphin can be secreted outside the cell in E. coli BL21 after codon optimization, which is a rare phenomenon of achieving lysostaphin secretion in prokaryotic cells. In this study, the secretion of lysostaphin was also achieved, and the growth of host bacteria was not inhibited during the induction process. Therefore, this lays the foundation for the subsequent establishment of a double-layer plate method to detect extracellular lysostaphin activity.
[0115] 2.2. Analysis of Staphylococcus aureus bactericidal activity
[0116] In order to determine the lytic activity of the lysostaphin expressed by EcN, the plate sterilization method was first used. The fermentation supernatant of EcN was able to produce a large and obvious S. aureus inhibition zone on the upper layer of the plate ( Figure 2 A), indicating that the EcN strain can secrete and express active lysostaphin.
[0117] exist Figure 2 In B and 2C, when EcN expressing lysostaphin and control strains were inoculated on double-layer plates containing S. aureus, the activity of lysostaphin was judged by the size of the inhibition zone around the colonies. Figure 2 As shown in B, EcN / 28a-Lys can produce a transparent circle outside the cell, while EcN / 28a cannot produce a transparent circle around the colony ( Figure 2 C), further indicating that the strain can secrete and express soluble lysostaphin. The colonies with superior inhibition zone on the plate were extracted into LB medium and induced with IPTG. After 36 hours, the enzyme activity of the fermentation broth supernatant was measured. 10.0 μg / mL of lysostaphin can increase the OD of Staphylococcus aureus to 600nm The concentration of 1% β-catenin was reduced from 0.8 to 0.2 within 20 min until the Staphylococcus aureus solution became clear ( Figure 2 D).
[0118] 2.3. Transmission electron microscopy analysis of lysostaphin-treated S. aureus
[0119] Transmission electron microscopy (TEM) was used to observe the cell morphology of Staphylococcus aureus treated with lysostaphin. Without any treatment, the bacterial cell surface was smooth and bright, and no content flow was observed ( Figure 3 A and 3B). Compared with the control, after 3 minutes of lysostaphin treatment, the cells ruptured and the contents flowed out ( Figure 3C and 3D), as time goes by, the bacterial solution is completely degraded and becomes clear, and a small number of cells are observed in the field of view. In TEM analysis, the rupture or degradation of the bacterial cell membrane of Staphylococcus aureus treated with lysostaphin was also confirmed.
[0120] 2.4. Detection of Staphylococcus lysogeny properties
[0121] A series of tests were conducted to characterize the properties of the lysostaphin secreted by EcN. The optimal temperature for lysostaphin is 37°C ( Figure 4 A). It exhibits bactericidal activity under neutral and alkaline conditions, with high bactericidal activity at pH 7.0-10.0, and the highest activity observed at pH 9.0 ( Figure 4 B). The relative bactericidal activity was inhibited at pH 3.0-6.0, and about 18% of the activity was retained at pH 5.0. Therefore, it is assumed that lysostaphin is an alkaliphilic endoplasmic enzyme. Figure 4 C. Lysostaphin can maintain more than 80% of its enzyme activity at 4℃~55℃, and its enzyme activity suddenly drops at 55℃~60℃. We all know that protein stability is an important indicator for identifying good properties of an enzyme. Although the stability properties of lysostaphin observed are slightly better than those of other phage lysins, there is still room for further improvement. In subsequent studies, our goal is to obtain mutant proteins with improved thermal stability.
[0122] Regardless of whether the final concentration of divalent metal cations in the system is 0.5 mM or 1.0 mM, Zn 2+ , Cu 2+ , Mn 2+ and Mg 2+ Lysostaphin, Ca 2+ and Mg 2+ Almost no effect, Mn 2+ Only slightly inhibited enzyme activity, but Zn 2+ and Cu 2+ Significantly inhibited enzyme activity. This indicates that divalent metal cations have different degrees of inhibitory effects on the lysostaphin activity of lysostaphin. These results may be related to the fact that lysostaphin is a metal ion-dependent peptidase.
[0123] 2.5. Detection of the bactericidal spectrum of Staphylococcus aureus
[0124] To evaluate the lytic spectrum of lysostaphin, nine environmental isolates of S. aureus (DZ25, DZ04, DZ02, TA22, 2-3, 2hun, WF107, LY05, LY53), one standard strain of S. aureus (ATCC 6538), and eight Gram-negative strains (Acinetobacter baumannii AB1, Klebsiella pneumoniae K3, Pseudomonas aeruginosa PA01, DH5α, BL21 (DE3), JM109, MG1655, and Min O157) were studied. Lysostaphin showed a good bactericidal spectrum against S. aureus, and the results are shown in Table 2. As expected, lysostaphin did not show as much bactericidal activity against pathogens of other genera. Therefore, the bactericidal spectrum of lysostaphin was limited to the genus Staphylococcus.
[0125] Table 2 Lysostaphin against S. aureus and Gram-negative bacteria
[0126]
[0127]
[0128] “-”, lytic activity less than 10%; “+”, lytic activity between 10% and 30%; “++”, lytic activity between 30% and 50%; “+++”, lytic activity between 50% and 70%; “++++”, lytic activity between 70% and 100%.
[0129] 2.6. Stability modification of lysostaphin
[0130] 2.6.1. Stability determination of disulfide bond mutation products
[0131] Design of two regions in Lysostaphin as potential Zn 2+ Ion binding region. Region 1 contains Asp320, Glu252 and Asn319, and region 2 contains Asp450 and Arg470. Subsequently, four pairs of N319C / E252C, D320C / E252, D450C / R470C and N319C / D320C were designed for disulfide bond mutation (cysteine substitution mutation), and a total of four disulfide bond mutant proteins N319C / E252C, D320C / E252, D450C / R470C and N319C / D320C were generated. Among them, the stability of the N319C / E252C mutant protein was improved the most.
[0132] 2.6.2. Stability test of the product of short peptide mutation
[0133] SDS-PAGE revealed that the bands of Lys, Lys-G4S and Lys-GGG were clear, and Lys-GGG showed the fastest bactericidal activity. It was found that the supernatant of Lys-GGG fragments remained stable at higher temperatures. Therefore, we introduced a short peptide at the carboxyl terminus of lysostaphin to modify it. The results were consistent with our expectations. Compared with the parent, the heat resistance of the mutant protein was improved ( Figure 5 ).
[0134] 2.6.3. Stability testing of combined mutation products
[0135] In order to further improve the genetic thermal stability of the mutant strains, the two strategies were combined and mutated, and the proteins expressed by each mutant strain were subjected to Ni column affinity chromatography, and the concentrations of each protein were adjusted to be consistent. The bactericidal activity of lysostaphin was detected by turbidity, and it was found that the stability of the mutant proteins of the 319 / 252 series was improved, especially N319C / E252C-GGG, which was 2.6 times higher than Lys after being incubated at 60°C for 30 minutes. The inactivation inflection point of Lys was 55-60°C, while the inactivation inflection point of N319C / E252C-GGG was increased to 65-70°C ( Figure 5 ). And of course, the stability of N319C / E252C-GGG is significantly higher than that of the protein products N319C / E252C and Lys-GGG of the single mutation strategy.
[0136] 2.7. Application of Lysostaphin in Sterilization of Milk and Buffers
[0137] 10 μL of fermentation supernatant was mixed with 190 μL of exponential growth (OD 600nm =0.4~0.6) Staphylococcus aureus cells were incubated at 37℃ (the Staphylococcus aureus cells were washed once with Tris-HCl buffer and then resuspended in buffer or milk). Samples were taken regularly, diluted at appropriate multiples, then spread in LB medium and counted after incubation at 37℃ for 12 hours. It was found that the final concentration of 10.0μg / mL of lysostaphin in the buffer reaction system could reduce the Staphylococcus aureus strain by 5.1log in 10 minutes and 6.1log in 20 minutes ( Figure 6 B). In the milk reaction system: Staphylococcus aureus with a final concentration of 10.0 μg / mL at 37°C reduced the standard strain of Staphylococcus aureus by 2.5 log in 15 minutes, 4.6 log in 30 minutes, 5.7 log in 90 minutes, and 7.4 log after 120 minutes. The final colony count was only about 2.8 log ( Figure 6 A) The results of this test provide the basis for future clinical trials.
[0138] 2.8. Application of EcN-Lys for Control of Staphylococcus aureus
[0139] Although lysostaphin has been shown to be effective in preventing and removing staphylococcal infections in the mammary glands of dairy cows, it may provide a reference for the future treatment of bovine mastitis. However, faced with enzyme purification and loss, protein residues in milk, and the inflammatory storm produced by the rapid reaction of lysostaphin, it is necessary to reduce the reaction cost and reduce the extensive downstream purification process. To this end, the use of probiotic EcN-Lys whole cells to catalyze the lysis of pathogenic bacteria in milk was proposed.
[0140] The EcN-Lys(To) strain ( Figure 7 A and 7B), it has bactericidal activity without IPTG induction, and the lysostaphin activity in the supernatant of the broken liquid is equivalent to the enzyme activity in EcN-Lys(T) induced by IPTG ( Figure 8 B). The activity in the fermentation supernatant is only 1 / 2 of that of EcN-Lys(T), but it still has the function of secreting lysostaphin ( Figure 8 A). Subsequently, EcN-Lys(To) and EcN-Lys(T) strains can be used for whole-cell catalytic lysis of pathogenic bacteria in milk. EcN-Lys(To) was further co-cultured with Staphylococcus aureus, and the growth of Staphylococcus aureus was counted. EcN-Lys(To) and EcN-Lys(T) could reduce the number of Staphylococcus aureus colonies by 2.3log and 1.16log after 24h; by 2.53log and 1.7log after 48h; and by 2.1log and 2.57log after 72h, respectively. Fig. 9 ).
[0141] As far as we know, EcN is only used to produce omega-3 fatty acids, hepatic acid and 5-aminolevulinic acid. The strategy of using probiotics expressing lysostaphin to control bacterial infection in milk was first proposed. This study successfully used probiotic whole cells to eliminate Staphylococcus aureus in milk, laying the foundation for the application of lysostaphin in the food sterilization industry.
[0142] In summary, firstly, constitutive secretion and expression of lysostaphin in probiotic EcN was achieved, and the obtained recombinant lysostaphin had good bactericidal activity and relatively broad spectrum. Lysostaphin was further modified to obtain a mutant protein with higher thermal stability compared with the original protein. Based on the above characteristics, we established a low-cost and simple method, that is, to control the growth of pathogenic bacteria by co-culturing EcN-Lys with pathogenic Staphylococcus aureus in food (milk). This laid the foundation for the application of lysostaphin in the food sterilization industry.
[0143] Finally, it should be noted that the above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art can still modify the technical solutions described in the aforementioned embodiments or replace some of the technical features therein by equivalents. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A lysostaphin variant, It is characterized in that The lysostaphin variant is mutated on the basis of lysostaphin, and the lysostaphin variant is selected from the mutants shown below: Mutant: E252C / N319C; The lysostaphin variant is also modified with a short peptide; the short peptide is (GGG) n , n is a natural number from 1 to 3; the short peptide is modified at the carboxyl end of the lysostaphin variant; The amino acid numbering of the lysostaphin is based on the first amino acid residue alanine in the amino acid sequence shown in SEQ ID NO.1 as the 248th amino acid residue position, and the numbering is continued in sequence.
2. The lysostaphin variant according to claim 1, It is characterized in that n is taken from 1.
3. A polynucleotide, It is characterized in that The polynucleotide encodes the lysostaphin variant according to claim 1 or 2.
4. A recombinant expression vector, It is characterized in that The recombinant expression vector contains the polynucleotide according to claim 3.
5. The recombinant expression vector according to claim 4, It is characterized in that The recombinant expression vector is obtained by effectively connecting the polynucleotide according to claim 3 to an expression vector, wherein the expression vector is any one or more of a viral vector, a plasmid, a phage or an artificial chromosome, and the plasmid is pET28a.
6. The recombinant expression vector according to claim 5, It is characterized in that The inherent T7 promoter in the pET28a vector was replaced with the Tac promoter; and the site of the Lac O operator in the pET28a vector was mutated.
7. A host cell, It is characterized in that The host cell contains the recombinant expression vector according to any one of claims 4 to 6 or the chromosome is integrated with the polynucleotide according to claim 3; The host cell is a bacterium or a fungus.
8. The host cell according to claim 7, It is characterized in that The host cell is recombinant Escherichia coli EcN.
9. A microbial agent, It is characterized in that It comprises the host cell according to claim 7 or a fermentation product thereof.
10. Use of the lysostaphin variant of claim 1 or 2, the polynucleotide of claim 3, the recombinant expression vector of any one of claims 4 to 6, the host cell of any one of claims 7 to 8 or the microbial agent of claim 9 in the field of food sterilization; the sterilization is to kill Staphylococcus aureus.
11. The use according to claim 10, It is characterized in that The application environment is a normal temperature or high temperature environment, and the high temperature environment is not less than 30°C.
12. The use according to claim 11, It is characterized in that The high temperature environment is not less than 65°C.
13. A method for sterilizing food. It is characterized in that The method comprises adding the host cell according to any one of claims 7 to 8 or the microbial agent according to claim 9 to food; Wherein, the sterilization is to kill Staphylococcus aureus; The food is food infected by Staphylococcus; The host cell is recombinant Escherichia coli EcN.
14. The method for sterilizing food according to claim 13, It is characterized in that The food is susceptible to Staphylococcus infection.
15. The method for sterilizing food according to claim 13, It is characterized in that The food is liquid food, including milk and dairy products.
